EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study

Ayaka Isogai, Kazuki Nozawa, Akira Nakakami, Rie Komaki, Yuri Ozaki, Yuka Endo, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07367-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Ayaka Isogai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Trastuzumab deruxtecan (T-DXd) can improve the prognosis of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, data on treatment recommendations after T-DXd are lacking. Thus, this study aimed to evaluate the treatment options after T-DXd and their effectiveness. METHODS: Patients with HER2-positive MBC were included in this study. Data from clinical records were retrospectively analyzed. The primary outcome was time to treatment failure (TTF). Secondary endpoints were TTF of each treatment and first-line treatment after interstitial lung disease (ILD) and overall survival (OS). RESULTS: A total of 29 patients were included. Among them, 18 (62%) were hormone receptor-positive. All patients had a median TTF (mTTF) of 3.5 months (95% confidence interval (CI) 2.1-10.03). The mTTF of each treatment, including HER2 tyrosine kinase inhibitor (HER2 TKI), other anti-HER2 treatments, and other treatments, was 2.6, 8.8, and 3.8 months, respectively. No significant differences were observed between treatments, but regimens that include trastuzumab showed a longer TTF than TKI. However, the mTTF among patients who developed T-DXd-related ILD was 2.33 months (95% CI 0.7-not reached), which was shorter than that among those who did not develop ILD (3.83 months, 95% CI 2.1-10.03, hazard ratio: 2.046, 95% CI 0.760-5.507, p = 0.258). The median OS was 14.9 months (95% CI 11.07-29.17). CONCLUSION: Treatments after T-DXd showed a shorter mTTF. Regimens that include trastuzumab may be more effective post-T-DXd treatment than HER2 TKI. Further data are needed to establish the best sequential treatment after T-DXd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedRetrospective StudiesAgedAdultCamptothecinNeoplasm MetastasisTreatment OutcomeImmunoconjugatesAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalPrognosis

Stichwörter der Autor:innen

HER2-positiveMetastatic breast cancerPost treatmentTime to treatment failure/TTFTrastuzumab deruxtecan/ T-DXd

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinImmunoconjugatesAntineoplastic Agents, Immunologicaltrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
  • Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. k.nozawa@aichi-cc.jp.
  • Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. k.nozawa@aichi-cc.jp.
  • Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Zitieren

APA

Isogai, A., Nozawa, K., Nakakami, A., Komaki, R., Ozaki, Y., Endo, Y., Kataoka, A., Kotani, H., Yoshimura, A., Hattori, M., Sawaki, M., & Iwata, H. (2024). Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07367-x

Vancouver

Isogai A, Nozawa K, Nakakami A, Komaki R, Ozaki Y, Endo Y, et al. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07367-x

BibTeX
@article{Isogai2024,
  author = {Isogai, Ayaka and Nozawa, Kazuki and Nakakami, Akira and Komaki, Rie and Ozaki, Yuri and Endo, Yuka and Kataoka, Ayumi and Kotani, Haruru and Yoshimura, Akiyo and Hattori, Masaya and Sawaki, Masataka and Iwata, Hiroji},
  title = {Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07367-x}
}
Kostenlos starten →